Recent 8-K filings for TGTX

• June 3, 2026, 7:34 AM ET other material materiality 0.75 positive item 8.01item 9.01

  TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV

  Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.

• May 27, 2026, 4:34 PM ET other material materiality 0.90 positive item 8.01item 9.01

  TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing

  Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.

• May 6, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics Q1 BRIUMVI US rev $194.8M; raises FY guidance to $885-900M

  Q1 2026 total global revenue approx $205M; BRIUMVI U.S. net product revenue $194.8M (+63% YoY).

• March 20, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings◈ Material Agreements

  TG Therapeutics establishes $750M term loan facility due 2031, repays prior term loans

  Borrowed $750M on March 18, 2026 under new term loan; proceeds used to fully repay initial term loans.

• February 26, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M

  Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).

• January 13, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M

  Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.

• November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M

  Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.

• August 4, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M

  Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.

• May 5, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  TG Therapeutics Q1 BRIUMVI sales $119.7M (+137% YoY); raises FY revenue guidance

  Q1 2025 BRIUMVI U.S. net revenue $119.7M vs $50.5M YoY, up ~137%.

• March 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M

  Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.

• January 14, 2025, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M

  Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.

• November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M

  BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.

• August 6, 2024, 7:59 PM ET earnings materiality 0.85 positive item 1.01item 1.02item 2.2item 2.02item 8.01item 9.01

  TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness

  Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.

• June 17, 2024, 7:59 PM ET other material materiality 0.80 neutral item 5.02item 5.07item 5.03item 9.01

  TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting

  Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M

  BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.

• February 28, 2024, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M

  BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.

• January 10, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M

  Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.80 · Most common event earnings

15 positive 0 negative 3 neutral

source · TGTX on sec.gov